Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6, 12, 18 and 24 months
Awards & highlights
Study Summary
The goal of this international observational study is to learn about the natural history of Danon disease in male patients >8 years of age. The key objectives include assessing change over time in cardiac structure (left ventricular mass and wall thickness), cardiac biomarkers, symptoms, and quality of life and the incidence of clinical events such as HF hospitalization, cardiac transplantation, and death.
Eligible Conditions
- Danon Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6, 12, 18 and 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6, 12, 18 and 24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Left Ventricular Mass Index (LVMI) by echocardiogram
Secondary outcome measures
Cardiac biomarkers (NT-proBNP, BNP)
Cardiac biomarkers (hsTnI)
Event free survival with events defined as death, heart transplant, mechanical circulatory support (MCS) or heart failure hospitalization
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Retrospective onlyExperimental Treatment1 Intervention
Group II: ProspectiveExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Rocket Pharmaceuticals Inc.Lead Sponsor
14 Previous Clinical Trials
334 Total Patients Enrolled
4 Trials studying Danon Disease
278 Patients Enrolled for Danon Disease
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger